The proposed project seeks funding to support attendance at The American Society of Hematology (ASH) 57th Annual Meeting and Exposition in December 2015. ASH is the largest meeting dedicated solely to benign and malignant hematology, where the latest in basic science, translational, and clinical hematologic research is presented and where future collaborative research concepts are discussed and developed between investigators at various institutions and biotechnology/pharmaceutical companies. I have attended the ASH annual meeting every year since 2012 and have presented abstracts at each of these meetings. I have also met with other investigators and pharmaceutical companies to move projects forward. Funds for the proposal would pay for the meeting registration fee, airfare, and hotel stay. This will permit presenting potential abstracts but also allow networking. In particular, I plan to continue collaborations for an investigator-initiated phase I/II clinical trial that I developed and wrote as a fellow at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, the phase I trial is pending final Institutional Review Board approval at MSKCC and will soon open. Discussion has already been held regarding opening the future phase II trial at multiple sites, including possibly the University of Michigan. This networking to foster other research projects and bringing clinical trials to the University of Michigan are emblematic of the importance of ASH. This will benefit my clinical training and research career as a young investigator at Michigan. It will also greatly influence the care of the leukemia patients I treat in the Cancer Center.